<style type="text/css">body .wpex-vc-row-stretched, body .vc_row-o-full-height { visibility: visible; }</style> skip to Main Content


Galmed Pharmaceuticals to Report Full Year and Fourth Quarter 2017 Financial Results and Provide Business Update on Tuesday, March 13

TEL AVIV, Israel, March 5, 2018 /PRNewswire/ --

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmedˮ or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH and other liver diseases, announced today that it will host a conference call and webcast on Tuesday, March 13th, 2018, to provide an update on current developments with respect to its clinical programs for Aramchol™ and to discuss financial results for the three months and full year ended December 31, 2017.

Galmed Pharmaceuticals

Conference Call & Webcast:

Tuesday, March 13th @ 8:30am Eastern Time

Toll-Free:                              1-800-289-0438
Toll/International:                   1-323-794-2423
Conference ID:                      1228226
Webcast:                              http://public.viavid.com/index.php?id=128520

Replays available through March 27, 2018

Toll-Free:                              1-844-512-2921
Toll/International:                   1-412-317-6671
Replay PIN:                           1228226

About Aramchol™ and Non-alcoholic Steatohepatitis (NASH)

Aramchol™ (arachidyl amido cholanoic acid) is a novel fatty acid bile acid conjugate, inducing beneficial modulation of intra-hepatic lipid metabolism. Aramchol™'s ability to modulate hepatic lipid metabolism was discovered and validated in animal models, demonstrating downregulation of the three key pathologies of NASH: steatosis, inflammation and fibrosis. The effect of Aramchol™ on fibrosis is mediated by downregulation of steatosis and directly on human collagen producing cells. Aramchol™ has been granted Fast Track designation status by the FDA for the treatment of NASH.

NASH is an emerging world crisis impacting an estimated 3% to 5% of the U.S. population and an estimated 2% to 4% globally. It is the fastest growing cause of liver cancer and liver transplant in the U.S. due to the rise in obesity. NASH is the progressive form of non-alcoholic fatty liver disease that can lead to cardiovascular disease, cirrhosis and liver-related mortality.

About Galmed Pharmaceuticals Ltd.

Galmed is a clinical-stage biopharmaceutical company focused on the development of Aramchol™, a first in class, novel, once-daily, oral therapy for the treatment of NASH for variable populations, as well as other liver associated disorders. Galmed is currently conducting the ARREST Study, a multicenter, randomized, double blind, placebo-controlled Phase IIb clinical study designed to evaluate the efficacy and safety of Aramchol™ in subjects with NASH, who are overweight or obese, and who are pre-diabetic or type-II-diabetic. More information about the ARREST Study may be found on ClinicalTrials.gov identifier: NCT02279524.



SOURCE Galmed Pharmaceuticals Ltd.

For further information: Bob Yedid, LifeSci Advisors, LLC, 646-597-6989, bob@lifesciadvisors.com; Guy Nehemya, VP Operations, Galmed Pharmaceuticals Ltd., guy@galmedpharma.com
Back To Top